Breast Oncologist and Professor of Cancer Informatics, Edinburgh | Health Economics | Real World Evidence | https://cancer-data.ecrc.ed.ac.uk/https://bsky.app/profile/peterhall001.bsky.socialhttps://bsky.app/profile/peterhall001.bsky.social/post/3lxjpyto64s2qAdjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial - The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2825%2900832-3/fulltext29 Aug 2025 09:17 +0000at://did:plc:54vcsoyo4jevjuni6m2owvas/app.bsky.feed.post/3lxjpyto64s2qhttps://bsky.app/profile/peterhall001.bsky.social/post/3lwvh3cmhpc2ePreprint "The C-Index Multiverse" arxiv.org/abs/2508.14821 https://arxiv.org/abs/2508.1482121 Aug 2025 07:44 +0000at://did:plc:54vcsoyo4jevjuni6m2owvas/app.bsky.feed.post/3lwvh3cmhpc2ehttps://bsky.app/profile/peterhall001.bsky.social/post/3lnt3dnj25k23https://www.nature.com/articles/s41571-025-01001-5#citeas27 Apr 2025 20:22 +0000at://did:plc:54vcsoyo4jevjuni6m2owvas/app.bsky.feed.post/3lnt3dnj25k23https://bsky.app/profile/peterhall001.bsky.social/post/3liobu7iow22lToday is the 4th Edinburgh Breast Cancer Special Symposium #EBCSS25 www.ebcss.org https://www.ebcss.org/21 Feb 2025 07:29 +0000at://did:plc:54vcsoyo4jevjuni6m2owvas/app.bsky.feed.post/3liobu7iow22lhttps://bsky.app/profile/peterhall001.bsky.social/post/3licwo2o4dk2uA pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer https://www.nature.com/articles/s41523-025-00720-316 Feb 2025 19:10 +0000at://did:plc:54vcsoyo4jevjuni6m2owvas/app.bsky.feed.post/3licwo2o4dk2uhttps://bsky.app/profile/peterhall001.bsky.social/post/3lgzkdxmbrc2mAnnual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial - The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2824%2902715-6/fulltext31 Jan 2025 08:10 +0000at://did:plc:54vcsoyo4jevjuni6m2owvas/app.bsky.feed.post/3lgzkdxmbrc2mhttps://bsky.app/profile/peterhall001.bsky.social/post/3lcxyddear22w#SABCS24 FDA session highlighting need to consider Minimum Effictive Dose, not just Maximum Tolerated Dose. Reminds me of the GO2 trial in gastric ca last decade. Breast cancer drug development catching up? https://jamanetwork.com/journals/jamaoncology/fullarticle/278003310 Dec 2024 19:34 +0000at://did:plc:54vcsoyo4jevjuni6m2owvas/app.bsky.feed.post/3lcxyddear22whttps://bsky.app/profile/peterhall001.bsky.social/post/3lccwfvbrsc22The Sudlow Review on the challenges and opportunities for using UK linked healthcare data for research https://www.hdruk.ac.uk/helping-with-health-data/the-sudlow-review/02 Dec 2024 10:34 +0000at://did:plc:54vcsoyo4jevjuni6m2owvas/app.bsky.feed.post/3lccwfvbrsc22https://bsky.app/profile/peterhall001.bsky.social/post/3lc33pwiqf22pVery good to see more de-escalation trials publishing in HER2 positive early breast cancer. Here the HELEN-006 trial. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00581-3/abstract29 Nov 2024 07:48 +0000at://did:plc:54vcsoyo4jevjuni6m2owvas/app.bsky.feed.post/3lc33pwiqf22phttps://bsky.app/profile/peterhall001.bsky.social/post/3lbxbpfrtpk2pThis is how we should be doing Oncology trials - the Dutch SONIA trial looking at treatment sequencing of CDK 4/6 inhibitors in advanced breast cancer. A self funding efficiency trial! #oncsky https://www.nature.com/articles/s41586-024-08035-2#cite https://www.nature.com/articles/s41586-024-08035-2#citeas27 Nov 2024 19:24 +0000at://did:plc:54vcsoyo4jevjuni6m2owvas/app.bsky.feed.post/3lbxbpfrtpk2phttps://bsky.app/profile/peterhall001.bsky.social/post/3lbmbodkiy22aAny good starter packs out there for folks using routine healthcare data for cancer research? #oncsky #cancerinformatics #causalinference23 Nov 2024 10:24 +0000at://did:plc:54vcsoyo4jevjuni6m2owvas/app.bsky.feed.post/3lbmbodkiy22a